Chemotherapeutic Hope on the Horizon for Plasmodium Vivax Malaria?

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2002 Oct 11

PMID 12374849

Citations 6

Authors

Robert G Ridley

Affiliations

Soon will be listed here.

Citing Articles

Ganoderma terpenoid extract exhibited anti-plasmodial activity by a mechanism involving reduction in erythrocyte and hepatic lipids in Plasmodium berghei infected mice.

Oluba O Lipids Health Dis. 2019; 18(1):12.

PMID: 30636645 PMC: 6330487. DOI: 10.1186/s12944-018-0951-x.

Maturation of Plasmodium falciparum in multiply infected erythrocytes and the potential role in malaria pathogenesis.

Orjih A Parasitol Res. 2014; 113(11):4045-56.

PMID: 25120031 DOI: 10.1007/s00436-014-4073-8.

Inhibition of Plasmodium falciparum field isolates-mediated endothelial cell apoptosis by Fasudil: therapeutic implications for severe malaria.

Zang-Edou E, Bisvigou U, Taoufiq Z, Lekoulou F, Lekana-Douki J, Traore Y PLoS One. 2010; 5(10):e13221.

PMID: 20949056 PMC: 2951358. DOI: 10.1371/journal.pone.0013221.

Improved assessment of plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay.

Druilhe P, Brasseur P, Blanc C, Makler M Antimicrob Agents Chemother. 2007; 51(6):2112-6.

PMID: 17387158 PMC: 1891393. DOI: 10.1128/AAC.01385-06.

Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance.

Kongsaeree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw M Proc Natl Acad Sci U S A. 2005; 102(37):13046-51.

PMID: 16135570 PMC: 1201571. DOI: 10.1073/pnas.0501747102.

References

de Pecoulas P, Tahar R, Ouatas T, MAZABRAUD A, Basco L . Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol. 1998; 92(2):265-73. DOI: 10.1016/s0166-6851(97)00247-8. View

Greenwood B, Mutabingwa T . Malaria in 2002. Nature. 2002; 415(6872):670-2. DOI: 10.1038/415670a. View

Leartsakulpanich U, Imwong M, Pukrittayakamee S, White N, Snounou G, Sirawaraporn W . Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol Biochem Parasitol. 2002; 119(1):63-73. DOI: 10.1016/s0166-6851(01)00402-9. View

Peters W . Drug resistance in malaria parasites of animals and man. Adv Parasitol. 1998; 41:1-62. DOI: 10.1016/s0065-308x(08)60421-2. View

Young M, Burgess R . Pyrimethamine resistance in Plasmodium vivax malaria. Bull World Health Organ. 1959; 20(1):27-36. PMC: 2537796. View

Mendis K, Sina B, Marchesini P, Carter R . The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001; 64(1-2 Suppl):97-106. DOI: 10.4269/ajtmh.2001.64.97. View

Miller L, Baruch D, Marsh K, Doumbo O . The pathogenic basis of malaria. Nature. 2002; 415(6872):673-9. DOI: 10.1038/415673a. View

Hastings M, Sibley C . Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc Natl Acad Sci U S A. 2002; 99(20):13137-41. PMC: 130599. DOI: 10.1073/pnas.182295999. View

Tahar R, de Pecoulas P, Basco L, Chiadmi M, MAZABRAUD A . Kinetic properties of dihydrofolate reductase from wild-type and mutant Plasmodium vivax expressed in Escherichia coli. Mol Biochem Parasitol. 2001; 113(2):241-9. DOI: 10.1016/s0166-6851(01)00230-4. View

10.

Karunaweera N, Grau G, Gamage P, Carter R, Mendis K . Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci U S A. 1992; 89(8):3200-3. PMC: 48833. DOI: 10.1073/pnas.89.8.3200. View

11.

Winstanley P . Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health. 2001; 6(11):952-4. DOI: 10.1046/j.1365-3156.2001.00751.x. View

12.

Ridley R . Medical need, scientific opportunity and the drive for antimalarial drugs. Nature. 2002; 415(6872):686-93. DOI: 10.1038/415686a. View

13.

Pukrittayakamee S, Chantra A, Simpson J, Vanijanonta S, Clemens R, Looareesuwan S . Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000; 44(6):1680-5. PMC: 89932. DOI: 10.1128/AAC.44.6.1680-1685.2000. View

14.

Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White N . Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother. 2001; 45(11):3122-7. PMC: 90792. DOI: 10.1128/AAC.45.11.3122-3127.2001. View

15.

Chusacultanachai S, Thiensathit P, Tarnchompoo B, Sirawaraporn W, Yuthavong Y . Novel antifolate resistant mutations of Plasmodium falciparum dihydrofolate reductase selected in Escherichia coli. Mol Biochem Parasitol. 2002; 120(1):61-72. DOI: 10.1016/s0166-6851(01)00440-6. View

16.

Jensen N, Ager A, Bliss R, Canfield C, Kotecka B, Rieckmann K . Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. J Med Chem. 2001; 44(23):3925-31. DOI: 10.1021/jm010089z. View